antiviral agent

Antiviral agent is thiazolidin-4-one with anti-hepatitis B activity

2H-Pyrido[2',1':3,4]pyrazino[1,2-b]indazole-3-carboxylic acid, 6-(1, 1-Dimethylethyl)-6, 7-Dihydro-10 -(3-methoxypropoxy)-2-oxo-, (6R)- has antibacterial and antiviral activity and can be used to study Hepatitis B virus.

Antiviralagent 59 (compound 58) is a selective antiviral agent with drug-like properties, capable of inhibiting a broad spectrum of filoviruses. It demonstrates low off-target activity and inhibitory effects against replicative forms of Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV).

Antiviralagent 61 (compound Z40) serves as an effective antiviral agent with activity against Tomato Spotted Wilt Virus (TSWV), exhibiting an EC50 value of 252 µg mL. It increases the RNA expression of Ndufb9, COX6B, 7.1.2.2, E, COX5B, Ndufs4, and SDHB, while reducing the expression of Ndufb7, Ndufa5, and G.

Antiviralagent 62 (Compound 16 h) is an orally active antiviral agent that inhibits the activity of HIV with an IC50 value of 8 nM against HIV (MJ4).

Antiviralagent 65 (compound 9) is an antiviral agent targeting the H1N1 influenza virus, with an EC50 of 7 μg mL.

Antiviral agent 8, surpassing lead compounds crocin-1 and crocin-2, has been identified as a potent and promising candidate with enhanced antiviral activities.

Antiviral agent 5 is a crucial intermediate utilized in the development of antiviral agents that specifically target 3C and 3CL proteases, which includes the SARS-CoV-2 M pro enzyme.

Antiviral agent 17 (Compound 4) is an anti-infection compound with strong antiviral effects, demonstrated by an EC50 of 0.015 μM in a human replicon assay, and effective against murine norovirus. It has potential applications in studying infectious and malignant diseases[1].

Antiviral agent 18 (Compound 5) demonstrates significant antiviral activity against murine norovirus and holds potential for research in infectious and malignant diseases [1].

Antiviral agent 10 effectively inhibits the respiratory syncytial virus (RSV) [1], serving as a potent anti-viral compound.

Antiviral agent 14 is an antiviral compound that inhibits tobacco mosaic virus (TMV) with an EC50 of 135.5 μg mL and cucumber mosaic virus (CMV) with an EC50 of 178.6 μg mL.

Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral activity, inhibiting the rabies virus (EC50: 1.45 μM) and pseudotyped SARS-CoV-2 (EC50: 14.6 μM).

Antiviral agent 19 (Compound 3) is a selective inhibitor of the Zika virus (EC50: 1.3 μM) with low cytotoxicity.

Antiviral agent 6 showed excellent anti-TSWV effects in vivo (EC50: 188 mg L).

Antiviral agent 7 is a peptide-based coating that effectively eliminates viruses.

Antiviral agent 20 (Compound 17b) is a selective inhibitor of Zika virus (EC50: 4.5 μM) with low cytotoxicity.

Antiviral Agent 23, an effective inhibitor of enterovirus 71 (EV71) with an EC50 value of 94 nM, also exhibits potent suppression of METTL3 METTL14 activity. This compound is employed in the research of infections.

Antiviral agent 9 exhibits potent efficacy against HIV-1 with an EC50 value of 0.006 nM, indicating extremely low concentrations are sufficient to inhibit the virus. Additionally, it demonstrates a selectivity index (SI) nearly 300 times higher than that of tenofovir alafenamide fumarate (TAF), outlining its superior selectivity and potential safety profile.

Antiviral agent 25 (compound 6g), a novel non-peptide analog covalent inhibitor of SARS-CoV-2 3CL pro, exhibits robust inhibitory activity against both SARS-CoV-2 3CL pro and SARS-CoV-2 PL pro, with IC50 values of 0.118 µM and 0.448 µM, respectively. Furthermore, it demonstrates significant antiviral effects against SARS-CoV-2, achieving an EC50 value of 7.249 µM [1].

Antiviral agent 34 is an orally available, potent antiviral compound that inhibits influenza A and B viruses.Antiviral agent 34 inhibits the proliferation of influenza viruses by modulating RNA polymerase.Antiviral agent 34 is used in the study of viral infections.

Antiviral Agent 30 (Example 118) is an active compound against HCV and RSV with an inhibitory concentration (IC 50) of greater than 25μM [1].

Antiviral agent 36 (compound 27), a potent inhibitor of both dengue (DENV) and Zika (ZIKV) viruses, demonstrates replication inhibition with EC50 values of 100 nM for ZIKV-FLR, 90 nM for ZIKV-HN16, 210 nM for DENV-2, and 120 nM for DENV-3 [1].

Antiviral agent 35 (compound 4d) is a potent oral inhibitor of the influenza virus, targeting early stages of viral replication. It suppresses influenza-induced ROS accumulation, autophagy, apoptosis, and the inflammatory response mediated by the RIG-1 pathway in a mouse model of pulmonary infection. Its cytotoxicity is minimal in MDCK cells, with a CC50 greater than 800 μM, and it has anti-H1N1 (A Weiss 43) activity with an EC50 of 2.28 μM [1].